Comparison of Midodrine and Albumin in the Prevention of Paracentesis-induced Circulatory Dysfunction in Cirrhotic Patients A Randomized Pilot Study

被引:26
作者
Hamdy, Hassan [1 ]
ElBaz, Ahmed A. [1 ]
Hassan, Ahmed [1 ]
Hassanin, Omayma [2 ,3 ]
机构
[1] Ain Shams Univ, Dept Trop Med Gastroenterol & Hepatol, Cairo 11566, Egypt
[2] Ain Shams Univ, Dept Clin Pathol, Cairo 11566, Egypt
[3] Ain Shams Univ, Chem Med Res Ctr, Cairo 11566, Egypt
关键词
albumin; hepatocellular carcinoma; large-volume paracentesis; midodrine; paracentesis-induced circulatory dysfunction; TENSE ASCITES; THERAPEUTIC PARACENTESIS; HEPATORENAL-SYNDROME; INTRAVENOUS ALBUMIN; ORTHOSTATIC HYPOTENSION; HEPATIC HEMODYNAMICS; INFUSION; VASODILATION; TERLIPRESSIN;
D O I
10.1097/MCG.0b013e31829ae376
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Goals:In this pilot study, we compared midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction (PICD).Background:PICD with pronounced arterial vasodilatation in cirrhotics with tense ascites can be prevented by the infusion of albumin, which is an expensive treatment modality. Various vasoconstrictors have also been used to prevent PICD, but there are few studies about the usage of midodrine.Study:Fifty patients with cirrhosis and tense refractory ascites were randomly assigned to be treated with either midodrine (n=25) (12.5 mg 3 times/d; over 3 d) or albumin (n=25) (8 g/L of removed ascites) after a large-volume paracentesis. Effective arterial blood volume was assessed indirectly by measuring serum creatinine, serum sodium, plasma renin activity, and aldosterone concentration before and 6 days after paracentesis.Results:Midodrine therapy was cheaper compared with albumin therapy, but serum creatinine, serum sodium, plasma renin activity, and plasma aldosterone concentration values after treatment [0.990.19 to 3.02 +/- 2.58 mg/dL (P=0.001), 132.36 +/- 3.2 to 130.2 +/- 4.1 mEq/L (P<0.001), 3.03 +/- 0.33 to 4.2 +/- 0.76 ng/mL/h (P<0.001), and 166.72 +/- 64.26 to 298.64 +/- 130 pg/mL (P<0.001), respectively] significantly differed in the midodrine group from that in the albumin group [1.10 +/- 0.22 to 1.11 +/- 0.161 mg/dL (P=0.885), 132.2 +/- 3.524 to 131.88 +/- 3.09 mEq/L (P=0.246), 4 +/- 0.91 to 4.11 +/- 0.74 ng/mL/h (P=0.440), and 204.88 +/- 115.9 to 177.08 +/- 100.5 pg/mL (P<0.001), respectively]. Seven patients, among whom 6 were hepatocellular carcinoma (HCC) positive, in the midodrine group of our study died as a consequence of liver failure complicated by acute renal failure, followed by hepatic encephalopathy. Whereas in the albumin group, even among the 7 patients with HCC, no patient died or developed hepatorenal syndrome or developed hepatic encephalopathy.Conclusions:This pilot study suggests that midodrine is not as effective as intravenous albumin in preventing circulatory dysfunction after large-volume paracentesis in patients with cirrhosis and tense ascites, especially with HCC-positive patients.
引用
收藏
页码:184 / 188
页数:5
相关论文
共 34 条
[1]   Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: A case-control study [J].
Alessandria, C. ;
Debernardi-Venon, W. ;
Todros, L. ;
Rizzetto, M. ;
Marzano, A. .
JOURNAL OF HEPATOLOGY, 2007, 46 :S89-S90
[2]   Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide [J].
Angeli, P ;
Volpin, R ;
Gerunda, G ;
Craighero, R ;
Rone, P ;
Merenda, R ;
Amodio, P ;
Sticca, A ;
Caregaro, L ;
Maffei-Faccioli, A ;
Gatta, A .
HEPATOLOGY, 1999, 29 (06) :1690-1697
[3]   Acute effects of the oral administration of midodrine, an α-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites [J].
Angeli, P ;
Volpin, R ;
Piovan, D ;
Bortoluzzi, A ;
Craighero, R ;
Bottaro, S ;
Finucci, GF ;
Casiglia, E ;
Sticca, A ;
De Toni, R ;
Pavan, L ;
Gatta, A .
HEPATOLOGY, 1998, 28 (04) :937-943
[4]   Prevention of paracentesis-induced circulatory dysfunction:: midodrine vs albumin.: A randomized pilot study [J].
Appenrodt, Beate ;
Wolf, Andrea ;
Gruenhage, Frank ;
Trebicka, Jonel ;
Schepke, Michael ;
Rabe, Christian ;
Lammert, Frank ;
Sauerbruch, Tilman ;
Heller, J. .
LIVER INTERNATIONAL, 2008, 28 (07) :1019-1025
[5]   Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis [J].
Arroyo, V ;
Gines, P ;
Gerbes, AL ;
Dudley, FJ ;
Gentilini, P ;
Laffi, G ;
Reynolds, TB ;
RingLarsen, H ;
Scholmerich, J .
HEPATOLOGY, 1996, 23 (01) :164-176
[6]   Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management [J].
Arroyo, V ;
Colmenero, J .
JOURNAL OF HEPATOLOGY, 2003, 38 :S69-S89
[7]   Evaluation of nitric oxide as a novel diagnostic marker for hepatocellular carcinoma [J].
El Moety, Amr Aly Abd ;
El Moety, Hoda Abd .
ALEXANDRIA JOURNAL OF MEDICINE, 2011, 47 (01) :31-35
[8]  
GARCIACOMPEAN D, 1993, LIVER, V13, P233
[9]   Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis [J].
Gines, A ;
FernandezEsparrach, G ;
Monescillo, A ;
Vila, C ;
Domenech, E ;
Abecasis, R ;
Angeli, P ;
RuizDelArbol, L ;
Planas, R ;
Sola, R ;
Gines, P ;
Terg, R ;
Inglada, L ;
Vaque, P ;
Salerno, F ;
Vargas, V ;
Clemente, G ;
Quer, JC ;
Jimenez, W ;
Arroyo, V ;
Rodes, J .
GASTROENTEROLOGY, 1996, 111 (04) :1002-1010
[10]   RANDOMIZED COMPARATIVE-STUDY OF THERAPEUTIC PARACENTESIS WITH AND WITHOUT INTRAVENOUS ALBUMIN IN CIRRHOSIS [J].
GINES, P ;
TITO, L ;
ARROYO, V ;
PLANAS, R ;
PANES, J ;
VIVER, J ;
TORRES, M ;
HUMBERT, P ;
RIMOLA, A ;
LLACH, J ;
BADALAMENTI, S ;
JIMENEZ, W ;
GAYA, J ;
RODES, J .
GASTROENTEROLOGY, 1988, 94 (06) :1493-1502